Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib dose-ranging study in inadequately controlled moderate to severe asthma
jRCT2031230185Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of povorcitinib in asthma (4 arms), sponsored by Incyte. Primary endpoint: Absolute change in pre-bronchodilator FEV1. Started Jul 2023; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031230185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230185.